Recent News

• 03.30.2026 - RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update
• 03.26.2026 - RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment
• 03.23.2026 - RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement
• 03.20.2026 - RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET
• 03.18.2026 - RenovoRx Announces $10 Million at Market Private Placement
• 02.27.2026 - RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
• 02.26.2026 - RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
• 02.10.2026 - RenovoRx Establishes RenovoCath® Medical Advisory Board

Recent Filings

• 03.30.2026 - EX-99.1 EX-99.1
• 03.30.2026 - 8-K Current report
• 03.30.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2026 - 8-K Current report
• 03.27.2026 - 3/A Initial statement of beneficial ownership of securities
• 03.27.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2026 - 3 Initial statement of beneficial ownership of securities
• 03.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.24.2026 - 4 Statement of changes in beneficial ownership of securities